Breast Ultrasound Referrals Often Lack Important Info

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

There is a role forultrasound in breast cancer screening anddiagnosis, but many physicians do notseem to know what it is, according toAnnette Brown, MD, a radiologist in theMammography Division of Long IslandCollege Hospital in Brooklyn. A

NEW YORK--There is a role forultrasound in breast cancer screening anddiagnosis, but many physicians do notseem to know what it is, according toAnnette Brown, MD, a radiologist in theMammography Division of Long IslandCollege Hospital in Brooklyn. At the"Breast Cancer in Women of Color"meeting, Dr. Brown expressed her frustrationor "gripes" as she put it.

She called ultrasound the first line ofdefense for women under 40 who have amass, in order to spare them exams involvingradiation. "My gripe with anyphysician who is here," she said, "is whenyou send a patient for a sonogram, youcan't just say 'bilateral ultrasound' or 'ultrasoundright breast' and leave it at that.You have to say what you are looking for.Is there a mass in the breast? Where is it?Other than that, we're on a fishing expedition,and we may or may not find it."

Dr. Brown told ONI that she gets requestsfor bilateral ultrasounds every day."You have to waste your time callingthem. 'Excuse me, doctor, where is it?'Otherwise you are roaming around seeingwhat you bump into. If you cannotsay for sure that a mass is a simple cyst,then you have to do something about itand not say you didn't see it."

There are patients for whom such a"fishing expedition" makes sense, shesaid, eg, a young patient with densebreasts and a strong family history ofbreast cancer. "Because she has densebreasts, you are probably not going to seeanything on the mammogram. She deservesa second look with anything youhave. I think in a patient like that, youhave to go roaming around the breastand make sure there is nothing there.The problem, of course, is that such aggressivescreening can lead to more unnecessarybiopsies."

Women with dense breasts who havehad breast cancer also deserve screeningsonograms; even those without densebreasts deserve that second look, she said.'Of course, I explain the drawbacks tothe patient and the fact that we may notalways find an existing mass."

Although Dr. Brown feels ultrasoundis not ready for prime time as a breastscreening tool in the general population,still "it's a wonderful exam," she said. "Itgives us a lot of information and candistinguish between a cyst and a solidmass. However, since it is done with ahand-held transducer, if the technologistdoesn't put the transducer where theproblem is, we're not going to have apicture of it."

She further noted that ultrasound willnot find very small lesions in the breastor show lesions that have the same cysticproperties as the surrounding tissues ofthe breast. "The other problem is fattybreasts. I sometimes get a request for anultrasound, and find that the woman hasfatty breasts. Ultrasound doesn't like fat,"Dr. Brown said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content